DelveInsight’s, “Squamous Cell Carcinoma Pipeline Insight” report provides comprehensive insights about 75+ companies and 80+ ...

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

Shares of Exelixis EXEL were down 5.13% on Jan. 24, following a downgrade in rating by analysts at Oppenheimer. Oppenheimer ...

Oncolytics Biotech® Inc. , a leading clinical-stage company specializing in immunotherapy for oncology, today provided details from the abstracts featuring pelareorep ...

The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...

MAINZ, Germany, January 14, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today will present its 2025 strategic priorities and progress on the Company’s pipeline of ...

Matches between Real Madrid and Barcelona are always the biggest dates on the Spanish football calendar with the two grandest clubs in La Liga battling out some memorable contests over the years ...

“We see that 57% of the patients are disease free after undergoing surgery, and the delta is about 9% when compared with the pembrolizumab arm,” he continued. Turning to prognostic markers, Bedke ...

Somewhat unusually, it said it would also like to see "more information from the company about the comparison between pembrolizumab plus chemotherapy with atezolizumab plus chemotherapy." ...

Prolonged remission without aggressive multimodality therapy is rare. We report a case of a 87-year-old woman with metastatic sinonasal NC treated with palliative radiotherapy and pembrolizumab who ...